TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02256709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet
Description: single rising daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high caloric breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high caloric breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet low dose
Study: NCT00981058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: 800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles.
Study: NCT01210404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filibuvir
Description: Filibuvir, 600mg bid administered along with methadone on days 2-11
Study: NCT03823209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief HIV Prevention Counseling
Description: Participants will receive brief (15-minute) counseling on how to prevent HIV infection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief HIV Prevention Counseling
Description: Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
Study: NCT00704236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)
Description: 50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02064777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT03725891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162 mg
Description: Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study: NCT02544581

Intervention type: OTHER
Intervention: Soberlink combined with aftercare services
Description: Soberlink Alcohol Breath Analyzer System combined with aftercare services

Intervention type: OTHER
Intervention: Soberlink combined with aftercare services
Description: Soberlink Alcohol Breath Analyzer System combined with aftercare services
Study: NCT01168986

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulstar Multiple Impulse Therapy
Description: Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants perform an exercise to strengthen the deep neck flexors
Study: NCT03615443

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a comprehensive, non-invasive tumor sequencing test.
Study: NCT01206218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOT Regimen
Description: FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLO Regimen or FLOT Regimen
Description: FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Study: NCT01286051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follistim administration
Description: adminstation of FSH for ovulation induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follistim plus Ganirelix
Description: Follistim plus single injection of ganirelix
Study: NCT02949791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive surgery
Description: Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intra abdominal pressure HIPEC
Description: Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intra abdominal pressure HIPEC
Description: Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
Study: NCT04816110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mineralized plasmatic matrix with collagen membrane
Description: Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM and covered by collagen membrane

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mineralized plasmatic matrix (MPM) without collagen membrane
Description: Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM.
Study: NCT01862237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery.
Study: NCT02139007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Study: NCT01117363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention (rye porridge or wheat bread)
Description: A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention (rye porridge or wheat bread)
Description: A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
Study: NCT02447302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01974635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Therapy
Description: During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
Study: NCT03507569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C] Ro15-4513
Description: At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.
Study: NCT01523041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin)
Study: NCT03304938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavender Oil
Description: The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Study: NCT01594216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study: NCT03487705

Intervention type: OTHER
Group type: OTHER
Intervention: electromyographic essential tremor
Description: * Making a recording electromyographic recording of the essential tremors in each child included at prospective.~* Collect an electromyographic recording of essential tremors already made in each child included at retrospective.
Study: NCT00485784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test
Study: NCT02149901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine + 480 ml water
Description: 30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine + 50 ml water
Description: Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo + 480 ml water (optional)
Description: placebo PO with a pressor (480 ml) dose of drinking water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 50 ml water (optional)
Description: placebo PO with a non-pressor (50 ml) dose of drinking water
Study: NCT05808361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
Study: NCT03699215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
Study: NCT04473287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology practice
Description: Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
Study: NCT00135499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1200 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 2 mg/m², D1, D5, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg, D1, D5, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg, D1-D5, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 40 mg, D1-D5, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m², D1, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m², D1, 4 cycles
Study: NCT03749837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C- MAC VS
Description: The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Endoscope
Description: Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
Study: NCT03846908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCT
Description: patients will receive fat load with MCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCT
Description: patients will receive fat load with MCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCT
Description: patients will receive fat load with MCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA
Description: patients will receive fat load with SFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA
Description: patients will receive fat load with SFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA
Description: patients will receive fat load with SFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA
Description: patients will receive fat load with MUFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA
Description: patients will receive fat load with MUFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA
Description: patients will receive fat load with MUFA
Study: NCT04512612

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High definition white light colonoscopy
Description: Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
Study: NCT00030732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Capecitabine
Description: Gemcitabine + Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine alone
Description: Gemcitabine alone
Study: NCT00556504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-700C
Description: An add-on drug to conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, without acting ingredient.
Study: NCT02447523

Intervention type: PROCEDURE
Intervention: Elective abdominal surgery

Intervention type: PROCEDURE
Intervention: Elective abdominal surgery
Study: NCT02932241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Dialectical Behavior Therapy Skills Training
Description: 8, 50 minute skill training sessions made available to participants each week